VRCA Verrica Pharmaceuticals

Verrica Pharmaceuticals Announces Participation in the Jefferies 2018 London Healthcare Conference

Verrica Pharmaceuticals Announces Participation in the Jefferies 2018 London Healthcare Conference

WEST CHESTER, Pa., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced that the company will participate in the Jefferies 2018 London Healthcare Conference.

Ted White, President and CEO, will present and provide a business overview of the company’s pipeline programs on Wednesday, November 14, 2018 at 12:40 p.m. GMT.

A live audio webcast of the Jefferies 2018 London Healthcare Conference presentation will be available in the Investors/Events & Presentations section of the Verrica website at . A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. 

About Verrica Pharmaceuticals Inc.

Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company’s lead product candidate, VP-102, is currently being evaluated in two Phase 3 clinical trials for the treatment of molluscum contagiosum and in a Phase 2 clinical trial for the treatment of common warts.

Contacts

Chris Degnan

Chief Financial Officer

484.453.3300 ext. 103

Patti Bank

Managing Director

Westwicke Partners

415.513.1284

EN
01/11/2018

Underlying

VRCAVerrica Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Verrica Pharmaceuticals

 PRESS RELEASE
Free
VRCA Verrica Pharmac...

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Fina...

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results – YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year – – YCANTH dispensed applicator units grew 99% to 51,296 in 2025 versus 25,773 units in 2024 – Company is advancing VP-315, its novel oncolytic peptide, toward a Phase 3 program for basal cell carcinoma in 2026, further analysis supports abscopal effects and t...

20h / 15m 1 EN
 PRESS RELEASE
Free
VRCA Verrica Pharmac...

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Fi...

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December ...

March 5, 2026 1 EN
 PRESS RELEASE
Free
VRCA Verrica Pharmac...

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Hea...

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the TD Cowen 46th Annual Healthcare Conference in Boston. TD Cowen 46th Annual Health Care Conference, March 2-4, 2026Event details:Date: Monday,...

February 23, 2026 1 EN
 PRESS RELEASE
Free
VRCA Verrica Pharmac...

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Off...

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer. “It is my pleasure to welcome Chris Chapman to the Verrica team as our new Chief Commercial Officer,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer. “Chris has an extraordinary track r...

February 12, 2026 1 EN
 PRESS RELEASE
Free
VRCA Verrica Pharmac...

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment ...

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd. (“Torii”), a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum contagiosum (“molluscum”). “We would like...

February 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch